Bristol-Myers Squibb and Biocon’s Syngene International Extend PartnershipBy
Bristol-Myers Squibb Company and Syngene International, a contract research organization, have announced a five-year extension of their drug-discovery and development collaboration in India. Financial terms were not disclosed.
Since 2007, Bristol-Myers Squibb has been working with Syngene and its corporate parent, Biocon Ltd., to develop integrated capabilities in medicinal and process chemistry, biology, biotechnology, biomarkers, drug metabolism and pharmacokinetics, analytical research, and pharmaceutical development at the Biocon Bristol-Myers Squibb Research Center (BBRC) in Bangalore.
The collaboration has produced six drug candidates for further study and also helped Bristol-Myers Squibb reduce the time and costs associated with advancing new compounds to first-in-human studies, said Bristol-Myers Squibb in a company statement. One drug candidate currently in clinical trials was discovered at BBRC, and early nonclinical development work done at BBRC has enabled most of Bristol-Myers Squibb's small-molecule assets to advance to later stages of development over the last five years, said the company
Bristol-Myers Squibb and Syngene jointly developed the BBRC at Biocon Park in Bangalore. Over the years, BBRC has become Bristol-Myers Squibb's largest research and development center outside the United States, housing more than 400 scientists.
Source: Bristol-Myers Squibb